English
| dc.contributor.author | Bayazit, Y | |
| dc.contributor.author | Sirikci, A | |
| dc.contributor.author | Bayaram, M | |
| dc.contributor.author | Kanlikama, M | |
| dc.contributor.author | Demir, A | |
| dc.contributor.author | Bakir, K | |
| dc.date.accessioned | 2024-07-18T11:55:56Z | |
| dc.date.available | 2024-07-18T11:55:56Z | |
| dc.description.abstract | ELSEVIER SCI LTD | |
| dc.identifier.issn | 1879-1476 | |
| dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/6591 | |
| dc.language.iso | Editorial Material | |
| dc.publisher | 0385-8146 | |
| dc.subject | Histiocytosis X or Langerhans cell histiocytosis (LCH) is a disease that possesses three less distinctive and overlapping states called eosinophilic granuloma (EG)I Hand-Schuller-Christian (HSC) disease and Letterer-Siwe (LS) disease. EG is the least severe and localized form of all LCHs and possesses the best prognostic result. A high index of suspicion is required to diagnose the EG, especially when an ear disease is refractory to medical treatment. Early detection is important to manage the EG properly and to minimize the complications or sequels of treatment. Definitive diagnosis of histiocytosis is made by histopathological means and immunohistochemical detection of S-100 and CD1 antigens in the tissue samples. And differential diagnosis of the subgroups is made according to the clinical manifestations such as visceral organ or bone involvement. Surgical excision, radiotherapy and chemotherapy, either alone or in combination, are the main treatment options. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved. | |
| dc.title | English | |
| dc.type | LANGERHANS CELL HISTIOCYTOSIS |